TCGA-ZF-AA53-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 57.85151117
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.520
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.500
- INFLAMMATORY_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- MTORC1_SIGNALING+0.410
- PANCREAS_BETA_CELLS+0.410
- TNFA_SIGNALING_VIA_NFKB+0.410
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.150
- MITOTIC_SPINDLE-0.130
- UV_RESPONSE_DN-0.070
- BILE_ACID_METABOLISM+0.000
- ESTROGEN_RESPONSE_EARLY+0.000
- SPERMATOGENESIS+0.010
- G2M_CHECKPOINT+0.050
- KRAS_SIGNALING_DN+0.050
- ANDROGEN_RESPONSE+0.060
- FATTY_ACID_METABOLISM+0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-38-4629-01A-02R-1206-07 | — | cohortA1 | 0.933 |
| 2 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.924 |
| 3 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.922 |
| 4 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.919 |
| 5 | BS_9HSGV9TJ | pleomorphic xanthoastrocytoma(PXA) | — | 0.917 |
| 6 | TCGA-BH-A0DZ-01A-11R-A00Z-07 | — | C | 0.915 |
| 7 | BS_M8WP5T16 | low-grade glioma | — | 0.912 |
| 8 | MNG1029 | — | — | 0.912 |
| 9 | SRR1313165 | — | E | 0.911 |
| 10 | MDT-AP-2149 | Med | Medulloblastoma | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |